IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1-like autoimmune disease.

Clin Exp Immunol. 1999 Feb;115(2):236-47. Unique Identifier : AIDSLINE MED/99132253
Skyllouriotis P; Skyllouriotis-Lazarou M; Natter S; Steiner R; Spitzauer S; Kapiotis S; Valent P; Hirschl AM; Guber SE; Laufer G; Wollenek G; Wolner E; Wimmer M; Valenta R; General & Experimental Pathology, Vienna General Hospital,; University of Vienna, Medical School, Vienna, Austria.

Abstract: Studies performed in mice together with the demonstration of increased levels of heart-specific autoantibodies, cytokines and cytokine receptors in sera from cardiomyopathy (CMP) patients argued for a pathogenic role of autoimmune mechanisms in CMP. This study was designed to analyse the presence of IgG anti-heart antibodies in sera from patients suffering from hypertrophic and dilatative forms of CMP as well as from patients with ischaemic heart disease and healthy individuals. Patients' sera were analysed for IgG reactivity to Western-blotted extracts prepared from human epithelial and endothelial cells, heart and skeletal muscle specimens as well as from Streptococcus pyogenes. The IgG subclass (IgG1-4) reactivity to purified human cardiac myosin was analysed by ELISA. While sera from CMP patients and healthy individuals displayed comparable IgG reactivity to a variety of human proteins, cardiac myosin represented the prominent antigen detected strongly and preferentially by sera from CMP patients. Pronounced IgG anti-cardiac myosin reactivity was frequently found in sera from patients with dilatative CMP and reduced ventricular function. ELISA analyses revealed a prominent IgG2/IgG3 anti-cardiac myosin reactivity in CMP sera, indicating a preferential Th1-like immune response. Elevated anti-cytomegalovirus, anti-enterovirus IgG titres as well as IgG reactivity to nitrocellulose-blotted S. pyogenes proteins were also frequently observed in the group of CMP patients. If further work can support the hypothesis that autoreactivity to cardiac myosin represents a pathogenic factor in CMP, specific immunomodulation of this Th1- towards a Th2-like immune response may represent a promising therapeutic strategy for CMP.
Keywords: JOURNAL ARTICLE Adolescence Adult Aged Antibodies, Bacterial/BLOOD Antibodies, Viral/BLOOD Autoantibodies/BLOOD Autoimmune Diseases/*IMMUNOLOGY Child Child, Preschool Female Human IgG/*IMMUNOLOGY Immunoglobulin Isotypes/IMMUNOLOGY Male Middle Age Muscle, Skeletal/IMMUNOLOGY Myocardial Diseases/*IMMUNOLOGY Myocardial Ischemia/IMMUNOLOGY Myocardium/IMMUNOLOGY Myosin/*IMMUNOLOGY Support, Non-U.S. Gov't *Th1 CellsKWDjournalarticleadolescenceadultagedantibodies,bacterial/bloodantibodies,viral/bloodautoantibodies/bloodautoimmunediseases/KWDimmunologychildchild,preschoolfemalehumanigg/KWDimmunologyimmunoglobulinisotypes/immunologymalemiddleagemuscle,skeletal/immunologymyocardialdiseases/KWDimmunologymyocardialischemia/immunologymyocardium/immunologymyosin/KWDimmunologysupport,non-uKWDsKWDgov'tKWDth1cells
990530
A9950896

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .